Given that a clinical study may require the same amount of time, human resources and funding resources no matter which regulatory scheme is followed, clinical investigators need to bear in mind the objectives and funding support for the planned study when choosing which legislation to adhere to. This article reviews various factors that may help determine which of the recently introduced pieces of legislation is applicable in the planning of a particular clinical study. We also aim to establish approaches to identify the appropriate law and to enable non-clinical studies to move forward to the clinical study phase.
In Japan, in vivo diagnostic radiopharmaceuticals ("radiopharmaceuticals") are approved as either "drugs" or "medical devices" under the Pharmaceuticals and Medical Devices Law.
As described below, clinical studies using radiopharmaceuticals in humans can be classified into five categories Annals of Nuclear Cardiology Vol. 
Definition of clinical studies
Each of the three regulations employs its own definitions of activities involved in clinical study, as follows. How to select the applicable law for conducting clinical studies using radiopharmaceuticals
The regulation applied to a clinical study using a radiopharmaceutical(s) on humans depends on several aspects of the study such as the approval status of the radiopharmaceutical(s) being used. Fig. 2 is a flow chart for selecting the applicable law for clinical studies using approved test drug (s). Fig. 3 shows how to select the applicable laws for clinical studies involving unapproved test drug (s). The first and second steps will determine whether or not the study needs to comply with the Pharmaceuticals and Medical Devices Law.
The next four steps, from third to sixth, will determine whether or not the study needs to comply with the Clinical Research
Law. If a planned study does not match either of the two laws, the Ethical Guideline should be applied instead.
In Figs. 2 and 3 , the first step to be considered in the flow chart is whether or not the drug being used for the study has been approved. The second step is to consider whether or not the clinical study data that will be obtained are intended to be used as part of the package for application for JMHLW approval. The third step is to consider whether or not the study is designed to evaluate the efficacy and/or safety of the drug being used for the study. The fourth step is to consider whether on-label or off-label instructions will be followed in terms of administration procedure, dosage, or target disease. The fifth step is to check whether or not the study is being funded by industry or by the supplier of the drug being used for the study.
The sixth step is to select the type of radiopharmaceutical to be used in the clinical study. By following these 6 steps, researchers can determine the appropriate law to apply to their clinical studies.
Variations in clinical studies
There Research". However, it is recommended that investigators consider the study design from a broader perspective.
Where a study aims to evaluate the safety and/or efficacy of therapeutic intervention including therapeutic drug (s) based on information obtained through imaging with radiopharmaceutical (s), the applicable law should be determined based on the objectives and design of the study.
3) When an approved radiopharmaceutical used as a standard measurement and an unapproved radiopharmaceutical used for testing purposes are administered to human subjects in a comparative study, for evaluating the safety (10, 11) and/or efficacy of unapproved drug, such a study can be 
Conclusions
In Japan, clinical studies to evaluate the pharmacokinetics, 
